|
|
||||||||
The Journal of Thoracic and Cardiovascular Surgery, Vol 91, 723-731, Copyright © 1986 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
W Flameng, R De Meyere, W Daenen, P Sergeant, V Ngalikpima, J Geboers, R Suy and G Stalpaert
The cardioprotective effect of the addition of the slow calcium-channel
blocker nifedipine to cardioplegic solution was tested in two double- blind
placebo controlled randomized studies. The first study included 24 patients
undergoing aortic-coronary bypass grafting, and the second included 24
patients undergoing aortic valve replacement. Nifedipine at a dose of 200
micrograms/L or placebo was added to St. Thomas' Hospital cardioplegic
solution. The following markers of ischemia were used: adenosine
triphosphate and its catabolites, creatine phosphate and inorganic
phosphate, determined in transmural left ventricular biopsy specimens taken
before, at the end of, and after aortic cross-clamping; hemodynamic
recovery 15 minutes after cessation of cardiopulmonary bypass; clinical
outcome in terms of the incidence of arrhythmias, low cardiac output,
positive inotropic support immediately after operation, and follow-up at 15
months. The main difference between the two studies was that myocardial
temperature during cross-clamping remained constant at 14 degrees C in
coronary bypass grafting but increased to 25 degrees C in valve operations
despite the application of the same amounts of cardioplegic solutions. This
lower temperature resulted in better preservation of high-energy phosphates
in coronary bypass operations as compared to the placebo group having valve
replacement operations. According to analysis of variance, a drug effect
could be demonstrated only in the aortic valve replacement study:
Accumulation of breakdown products of the adenine nucleotide pool was less
in the nifedipine group than in the placebo group (p less than 0.05).
Adenosine triphosphate decreased only to 84% in the nifedipine group and to
72% in the placebo group. Despite this adenosine triphosphate-sparing
effect, weaning from cardiopulmonary bypass was more difficult in the
nifedipine group. Left ventricular stroke work index 15 minutes after
bypass was decreased to 72% of the prebypass value in the nifedipine group
(t test, p less than 0.01) and only to 86% in the placebo group (p = NS).
In contrast, after the patients were admitted to the intensive care unit,
the incidence of low cardiac output tended to be lower in the nifedipine
group than in the placebo group: 33% versus 58% (p = NS). In conclusion,
ischemia-induced degradation of nucleotides as it occurs when myocardial
cooling is inadequate can be prevented by the addition of nifedipine to the
St. Thomas' Hospital cardioplegic solution. This effect, however, is not
associated with an improved clinical outcome.
ARTICLES
Nifedipine as an adjunct to St. Thomas' Hospital cardioplegia. A double- blind, placebo-controlled, randomized clinical trial
This article has been cited by other articles:
![]() |
S. C. Stoica, D. K. Satchithananda, C. Atkinson, P. A. White, A. N. Redington, M. Goddard, T. Kealey, and S. R. Large The energy metabolism in the right and left ventricles of human donor hearts across transplantation Eur. J. Cardiothorac. Surg., April 1, 2003; 23(4): 503 - 512. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. K. Podesser, S. Schwarzacher, W. Zwoelfer, T. M. Binder, E. Wolner, and R. Seitelberger COMPARISON OF PERIOPERATIVE MYOCARDIAL PROTECTION WITH NIFEDIPINE VERSUS NIFEDIPINE AND METOPROLOL IN PATIENTS UNDERGOING ELECTIVE CORONARY ARTERY BYPASS GRAFTING J. Thorac. Cardiovasc. Surg., November 1, 1995; 110(5): 1461 - 1469. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |